Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib with or without Irinotecan in Recurrent/Metastatic SCCHN
NCT00103259Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2005
- Primary completion
- Nov 2011
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by National Cancer Institute. Started Jul 2005; status: completed.
02
Drugs
bortezomib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00103259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00103259.